Related Experiment Video
Updated: Jun 21, 2026
07:54
Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Propofol pharmacokinetics in patients with obstructive jaundice
1Department of Anesthesiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Current Drug Delivery
|July 17, 2009
Summary
Obstructive jaundice does not significantly alter propofol pharmacokinetics. This study found similar distribution and elimination of propofol in patients with and without jaundice, suggesting no dose adjustment is needed.
Area of Science:
- Anesthesiology and Pharmacology
- Clinical Pharmacokinetics
Background:
- Obstructive jaundice can affect drug metabolism and elimination.
- Propofol is a widely used anesthetic agent whose pharmacokinetics may be altered by liver dysfunction.
Purpose of the Study:
- To investigate the impact of obstructive jaundice on the distribution and elimination of propofol.
- To compare propofol pharmacokinetic parameters in patients with and without obstructive jaundice.
Main Methods:
- A comparative study involving 15 patients with obstructive jaundice and 15 controls.
- Intravenous bolus administration of propofol (2-2.5 mg/kg) followed by 4-hour arterial blood sampling.
- High-performance liquid chromatography for propofol concentration measurement and compartmental analysis.
Main Results:
- Pharmacokinetic parameters, including volumes of distribution (V(SS), V(r), V) and total body clearance (Cl), were similar between groups (P>0.05).
- Elimination half-times (T(1/2)(alpha), T(1/2)(beta), T(1/2)(gamma)) did not differ significantly between patients with obstructive jaundice and controls.
- A three-compartment model adequately described propofol distribution and elimination in all participants.
Conclusions:
- Obstructive jaundice does not appear to significantly alter the pharmacokinetics of propofol.
- The distribution and elimination of propofol are comparable in patients with and without obstructive jaundice.
- Current propofol dosing regimens are likely appropriate for patients with obstructive jaundice.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:13Local Anesthetics: Pharmacokinetics
The potency and duration of action of local anesthetics (LAs) are determined by their pharmacokinetics. Pharmacokinetics describes how LAs are absorbed, distributed, metabolized, and eliminated from the body. When administered to the vascular tissues, LAs are quickly absorbed and enter the systemic circulation, reducing their localized effects. Adding vasoconstrictors such as epinephrine to LAs reduces their absorption into the systemic circulation, making them clinically effective. The...